Background: Coronary slow flow (CSF), characterized by delayed coronary perfusion without significant coronary artery stenosis, remains a diagnostic challenge due to its elusive pathophysiology. This retrospective study aimed to evaluate the association between the thrombin-antithrombin (TAT) complex and CSF.Patients and methods: Ninety-one CSF patients and 74 subjects with normal coronary flow were recruited in this cohort. Coronary artery blood flow was quantified using the thrombolysis in myocardial infarction frame count (TFC) method. Plasma TAT complex levels were measured via chemiluminescent immunoassay. Logistic regression analyses and a receiver operating characteristic (ROC) curve were performed to determine the predictive value of TAT for CSF.Results: Compared with patients without CSF, patients with CSF showed higher plasma levels of TAT complex, total cholesterol, and low-density lipoprotein cholesterol, all of which were also positively correlated with TFC. However, multivariate logistic regression identified TAT as the only independent predictor of CSF after adjustment (OR: 1.71, 95% CI: 1.39–2.10, p < 0.001). More specifically, ROC analysis revealed that a plasma TAT complex levels of 3.875 ng/ml predicted CSF with a specificity of 89.2% and a sensitivity of 62.6%.Conclusion: Elevated plasma TAT complex levels are strongly associated with CSF and may serve as a candidate diagnostic biomarker.
24 March 2026 in Frontiers in Cardiovascular Medicine
Background: Interleukin-6 (IL-6) is associated with the pathogenesis of heart failure (HF) and an increased HF risk in people without previous myocardial infarction. However, little is currently known about the correlation between IL-6 and acute decompensated heart failure (ADHF). Objective: To determine whether IL-6 could serve as a diagnostic biomarker for ADHF in Chinese patients without acute myocardial infarction. Patients and methods: A total of 122 patients were included in our study [58 ADHF, 64 chronic HF (CHF)]. Plasma IL-6 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured. Logistic regression analyses and a receiver operating characteristic (ROC) curve were performed to determine the diagnostic value of IL-6. Results: Plasma levels of IL-6 and NT-proBNP were higher in ADHF patients than CHF patients. IL-6 correlated positively with NT-proBNP, heart rate, and left ventricular end-diastolic dimension, and inversely with left ventricular ejection fraction. After adjustment, IL-6 remained independently associated with ADHF (OR = 1.461, 95% CI: 1.053–2.028, p = 0.023). The optimal cut-off value of IL-6 for ADHF diagnosis was 5.00 pg/mL, and the sensitivity, specificity, and Youden index were 81.0%, 87.5%, and 0.685, respectively. Conclusions: IL-6 is independently associated with ADHF and shows promising diagnostic accuracy. The cut-off of 5.00 pg/mL provides a novel reference for Chinese ADHF patients without AMI, offering clinical evidence for research on inflammation-related biomarkers of cardiovascular diseases. Combined use with NT-proBNP may enhance diagnostic accuracy, but prospective validation is needed.